Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B
Nov 19, 2026, 11:51

Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B

Wolfgang Miesbach, Head of Hemostasis/Hemophilia Center at Medical Clinic 2 at University Hospital Frankfurt, shared a post on LinkedIn:

“Beyond episomes: targeted gene insertion for haemophilia B. At ESGCT2026 Meagan O’Brien (Regeneron) presented the CRISPR-based targeted F9 insertion platform developed with Intellia Therapeutics. One of the talks that made me think about children.

Why go further than what we have?

  • The one approved liver-directed AAV therapy for haemophilia B works through non-integrating episomes.
  • Episomes can be lost when hepatocytes divide, a real concern in a liver that is still growing.
  • It relies on the hyperactive Padua variant to compensate for the low expression seen with wild-type F9.
  • Long-term durability in children therefore remains unknown.

The approach: two components, same day

  • rAAV8 delivers a promoterless wild-type F9 template.
  • An LNP then delivers Cas9 plus a single guide RNA, targeting albumin intron 1.
  • F9 is inserted at the ALB locus and expressed under the albumin promoter.
  • Wild-type FIX, not Padua, and an approach that could be suitable at any age.
  • Supporting rodent and primate data were shown; the manuscript is under review, so I will leave the figures to the authors.

Already in the clinic

  • BEYOND-9 (NCT06379789) is a two-part, open-label phase 1/2 study, currently recruiting.
  • Dose escalation and confirmation in adults first, then expansion to adolescents and children from two years of age.
  • Males with severe or moderately severe haemophilia B on FIX prophylaxis.”

Wolfgang Miesbach: Beyond Episomal Gene Therapy in Haemophilia B

Other posts featuring Wolfgang Miesbach on Hemostasis Today.